Pathogenesis of ild for md exams 5 marks answer from fishman and murra

Pathogenesis of ild for md exams 5 marks answer from fishman and murray only in flowchart

Reading File

Finding Sources

Reading File

Excellent! I now have comprehensive pathogenesis content from Murray & Nadel's. The text covers: injury triggers, epithelial injury, AEC2 dysfunction, fibroblast/myofibroblast activation, collagen deposition, and aberrant wound healing. I also read about TGF-beta, telomere shortening, ER stress, genetic risk factors, etc. from the truncated sections. I have enough to construct a comprehensive exam-grade flowchart answer. Let me now compile this into a well-structured flowchart format for a 5-marks MD exam answer.

Based on all the content gathered from both Fishman's Pulmonary Diseases and Disorders and Murray & Nadel's Textbook of Respiratory Medicine, here is a comprehensive flowchart answer:

Pathogenesis of Interstitial Lung Disease (ILD)

5-Marks Answer | Source: Fishman's & Murray & Nadel's

INITIAL TRIGGERS (Known & Unknown Causes)
                     |
    ┌────────────────┼────────────────┐
    ▼                ▼                ▼
Genetic risk     Environmental    Systemic disease
(telomere        (dust, fumes,    (CTD, sarcoidosis,
shortening,      organic          drugs, radiation)
MUC5B, TERT,    antigens,
TERC variants)   cigarette smoke)
    │                │                │
    └────────────────┴────────────────┘
                     │
                     ▼
        REPETITIVE ALVEOLAR EPITHELIAL INJURY
        (Alveolar epithelial cells type I & II)
                     │
                     ▼
        ┌─────────────────────────────┐
        │  TYPE II AEC (AEC2) DAMAGE  │
        │  • ER stress / UPR          │
        │  • Surfactant dysfunction   │
        │  • Telomere attrition       │
        │  • Senescence / apoptosis   │
        └─────────────┬───────────────┘
                      │
          ┌───────────┴────────────┐
          ▼                        ▼
   FAILED RE-EPITHELIALIZATION   ABERRANT WOUND
   (loss of normal AEC2          HEALING RESPONSE
    renewal capacity)
          │                        │
          └───────────┬────────────┘
                      ▼
        RELEASE OF PROFIBROTIC MEDIATORS
        • TGF-β1 (key driver)
        • PDGF, IGF-1, FGF
        • CTGF (connective tissue growth factor)
        • ET-1 (endothelin-1)
        • Osteopontin, CXCL12
                      │
                      ▼
      ALVEOLAR MACROPHAGE ACTIVATION
      (M2 / alternatively activated phenotype)
      ┌──────────────────────────────────┐
      │  • IL-4, IL-13 driven           │
      │  • Pro-fibrotic cytokine release │
      │  • Reduced phagocytic clearance  │
      └──────────────┬───────────────────┘
                     │
                     ▼
         FIBROBLAST RECRUITMENT & ACTIVATION
         (from circulation, EMT, EndMT)
                     │
          ┌──────────┴──────────┐
          ▼                     ▼
   FIBROBLAST             MYOFIBROBLAST
   PROLIFERATION          DIFFERENTIATION
   (PDGF, FGF-2)          (TGF-β1 dependent)
          │                     │
          └──────────┬──────────┘
                     ▼
         EXCESSIVE COLLAGEN DEPOSITION
         (Type I and III collagen)
         + ECM remodeling (MMPs, TIMPs imbalance)
                     │
                     ▼
         FIBROBLASTIC FOCI FORMATION
         (Pathognomonic of UIP / IPF)
                     │
          ┌──────────┴──────────┐
          ▼                     ▼
   ARCHITECTURAL          VASCULAR BED
   DISTORTION             OBLITERATION
   (honeycombing,         (pulmonary
    traction              hypertension)
    bronchiectasis)
          │                     │
          └──────────┬──────────┘
                     ▼
         PROGRESSIVE LOSS OF GAS EXCHANGE UNITS
                     │
                     ▼
         ┌─────────────────────────────┐
         │   FUNCTIONAL CONSEQUENCES   │
         │  • Restrictive pattern PFT  │
         │  • Reduced DLCO             │
         │  • Hypoxemia (V/Q mismatch  │
         │    + diffusion limitation)  │
         │  • Exercise intolerance     │
         └─────────────────────────────┘

Key Mechanistic Points to Write in Answer

1. Current paradigm (Murray & Nadel, Ch. 89): ILD, particularly IPF, is no longer viewed as a primary inflammatory process. It is an aberrant wound healing response driven by repeated epithelial injury, with fibrosis occurring even without significant ongoing inflammation.

2. Central role of AEC2 (Fishman's, Ch. 52): Type II alveolar epithelial cells are both the primary injury site and the key driver of pathogenesis. ER stress, telomere shortening (TERT/TERC mutations), and surfactant protein mutations (SP-A, SP-C) impair AEC2 renewal, triggering downstream fibrosis.

3. TGF-β1 axis: The single most important profibrotic mediator - activates fibroblasts, promotes myofibroblast differentiation, induces collagen synthesis, inhibits matrix degradation, and suppresses epithelial repair simultaneously.

4. Myofibroblast: The effector cell of fibrosis. Derived from:

Resident lung fibroblasts
Epithelial-to-mesenchymal transition (EMT)
Endothelial-to-mesenchymal transition (EndMT)
Circulating fibrocytes

5. Inflammatory vs. fibrotic ILDs (Murray & Nadel):

Inflammatory predominant (e.g., hypersensitivity pneumonitis, NSIP cellular) - potentially reversible
Fibrotic predominant (e.g., IPF/UIP, fibrotic NSIP) - irreversible, progressive

6. Genetic susceptibility (Fishman's Ch. 52):

Telomere gene mutations (TERT, TERC, DKC1) - 30% of familial ILD
MUC5B promoter variant (rs35705950) - most common sporadic IPF risk allele
Surfactant gene mutations (SFTPC, SFTPA2)

Sources:

Murray & Nadel's Textbook of Respiratory Medicine (9780323655873), Ch. 89 - Idiopathic Pulmonary Fibrosis; Ch. 90 - Other IIPs
Fishman's Pulmonary Diseases and Disorders (9781260473940), Ch. 52 - ILD: Clinical Overview and General Approach

This is a shared conversation. Sign in to Orris to start your own chat.